阿尔茨海默病患者的微生物群诱导认知和海马神经发生缺陷
Stefanie Grabrucker1,2, Moira Marizzoni3,4, Edina Silajdžić5
1Department of Anatomy and Neuroscience, University College Cork, Ireland.
Brain : a journal of neurology
|October 18, 2023
概括
阿尔茨海默病的症状可以通过患者的肠道微生物群转移到健康的老鼠身上,这表明了因果关系. 这突显了阿尔茨海默病进展中的肠道微生物群和海马神经发生.
科学领域:
- 神经科学是一个神经科学.
- 微生物学 微生物学
- 胃肠病学 胃肠病学
背景情况:
- 阿尔茨海默病 (AD) 是一种影响认知的神经退行性疾病.
- 在阿尔茨海默病患者中观察到肠道微生物群的改变,但它们的因果作用尚不清楚.
- 海马神经发生是对记忆和情绪至关重要的,在AD中受到影响的过程.
研究的目的:
- 研究阿尔茨海默病患者肠道微生物群在阿尔茨海默病的发病过程中的因果作用.
- 确定移植肠道微生物群对宿主生理和行为的影响.
- 探索肠道微生物群,系统因素和AD中的海马神经发生之间的联系.
主要方法:
- 从阿尔茨海默病患者和健康对照对无菌大鼠的便微生物群移植.
- 对接受者大鼠进行行为测试,以评估依赖于海马神经发生的功能.
- 鼠和海马体的新陈代谢分析.
- 在体外评估人类神经干细胞神经发生使用来自AD患者和对照者的血清.
主要成果:
- 在老鼠中,移植AD患者的微生物群损害了依赖海马神经发生的行为.
- 障碍严重程度与人类阿兹海默症患者的认知评分相关.
- 在老鼠的头部和海马体组织中观察到明显的代谢变化.
- 来自AD患者的血清在体外减少了人类细胞中的神经发生.
结论:
- 阿尔茨海默病患者的肠道微生物群可以将类似AD的症状传递给健康的接受者,从而建立起因果关系.
- 海马神经发生是一个关键的细胞过程,受肠道微生物群和AD的系统因素的影响.
- 这项研究强调了肠道微生物群在阿尔茨海默氏病的发病过程中的关键作用.
相关概念视频
Alzheimer's Disease: Overview
500
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
500
Role of Neurotransmitters in Memory
589
Neurotransmitters are integral to the brain's communication system, enabling neurons to transmit signals across synapses. This chemical exchange underpins various cognitive functions, including memory processes. The role of neurotransmitters in memory is multifaceted, influencing the encoding, consolidation, and retrieval of memories through their action on different neural circuits.
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
589
Alzheimer's Disease: Treatment
200
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
200


